SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Cohance Lifesciences Ltd

BSE: 543064 NSE: COHANCE ISIN: INE03QK01018
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Cohance Lifesciences Ltd belong to?
Cohance Lifesciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Cohance Lifesciences Ltd a good quality company?
Cohance Lifesciences Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Cohance Lifesciences Ltd undervalued or overvalued?
Cohance Lifesciences Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Cohance Lifesciences Ltd a good buy now?
Cohance Lifesciences Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd revenue growth is 13.9% for FY-2025 , which is above its 5 year CAGR of 7.5% , indicating faster growth.
Q.2 Gross Profit margin of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 35.2% for FY-2025 , which is below its 5 year median of 44.1% , indicating decreasing margins.
Q.3 Operating Profit Margin of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 31.34% for FY-2025 , which is below its 5 year median of 42.84% indicating decreasing margins.
Q.4 Net Profit Margin of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Net Profit Margin is 22.11% for FY-2025 , is below with its 5 year median of 30.69%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 35.2 44.1
Operating Profit Margin 31.34 42.84
Net Profit Margin 22.11 30.69
Q.5 Return on Asset of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Return on Asset is 10.02%, which is below its 5 year historical median of 20.18%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Return on equity is 14.2% for FY-2025 , which is below its historical median of 25.21%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Return on capital employed is 18.44% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 11.25%, indicating value creation.
Q.8 Cash conversion cycle of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Cash conversion cycle is 95 days, above its historical median of 89 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.45 0.66
ROE 14.2 25.21
ROCE 18.44 33.41
Cash Conversion Cycle 95 days 89 days
Q.9 Debt to Equity ratio of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Debt-to-Equity ratio is 0.05 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd Debt to cash flow from operations is 0.27 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Cohance Lifesciences Ltd?
Promoters hold 57.49% of the Cohance Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Cohance Lifesciences Ltd vs industry peers?
Cohance Lifesciences Ltd revenue CAGR is 7.51% , compared to the industry median CAGR of 5.51% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 1,197.6 138.8
Gross Profit 421.7 16.2
Operating Profit 375 16
Net Profit 265 5.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.45 0.79
ROE 14.2 9.17
ROCE 18.44 11.78
Cash Conversion Cycle (days) 95.46 76

Valuation & price assessment

Q.1 Stock return of Cohance Lifesciences Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -7.71% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - -7.7% -8.3% -69.8%
Q.3 Valuation ratios of Cohance Lifesciences Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 68.89 36.60 40.28
Price to Book 3.64 8.67 2.77
Price to Sales 6.77 12.89 2.65
EV to EBITDA 31.27 29.78 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Sai Life Sciences
8. Astrazeneca Pharma I
9. Piramal Pharma
10. Acutaas Chemicals
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×